WNT/β‐catenin signaling and hepatocellular carcinoma
Jack R. Wands, Miran Kim – 20 February 2014
Late hepatic artery thrombosis after pediatric liver transplantation: A cross‐sectional study of 34 patients
Jesper M. Kivelä, Silja Kosola, Teija Kalajoki‐Helmiö, Heikki Mäkisalo, Hannu Jalanko, Christer Holmberg, Mikko P. Pakarinen, Jouni Lauronen – 18 February 2014 – Hepatic artery thrombosis (HAT) after liver transplantation (LT) increases patient morbidity and mortality. Early HAT is considered to occur within the first month after LT, whereas late HAT occurs after the first month. Few studies have addressed late HAT after LT, especially in pediatric patients. Between 1987 and 2007, 99 patients (age < 18 years) underwent deceased donor LT.
Potential impacts of the Affordable Care Act on the clinical practice of hepatology
Jayant A. Talwalkar – 15 February 2014 – The Patient Protection and Affordable Care Act (ACA), along with the Health Care and Education Reconciliation Act, was signed into law and upheld by the Supreme Court earlier this year. The ACA contains a variety of reforms that, if implemented, will significantly affect current models of healthcare delivery for patients with acute and chronic hepatobiliary diseases.
Potential impacts of the Affordable Care Act on the clinical practice of hepatology
Jayant A. Talwalkar – 15 February 2014 – The Patient Protection and Affordable Care Act (ACA), along with the Health Care and Education Reconciliation Act, was signed into law and upheld by the Supreme Court earlier this year. The ACA contains a variety of reforms that, if implemented, will significantly affect current models of healthcare delivery for patients with acute and chronic hepatobiliary diseases.
Reply
Yasuhiro Asahina, Kaoru Tsuchiya, Namiki Izumi – 12 February 2014
Postinterferon α‐fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: Cause or results?
Hidenori Toyoda, Takashi Kumada, Toshifumi Tada – 12 February 2014
Blockade of CD47‐mediated cathepsin S/protease‐activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma
Terence Kin‐Wah Lee, Vincent Chi‐Ho Cheung, Ping Lu, Eunice Yuen Ting Lau, Stephanie Ma, Kwan Ho Tang, Man Tong, Jessica Lo, Irene Oi Lin Ng – 12 February 2014 – Identification of therapeutic targets against tumor‐initiating cells (TICs) is a priority in the development of new therapeutic paradigms against cancer. We enriched a TIC population capable of tumor initiation and self‐renewal by serial passages of hepatospheres with chemotherapeutic agents. In chemoresistant hepatospheres, CD47 was found to be up‐regulated, when compared with differentiated progenies.
Could postinterferon treatment α‐fetoprotein levels truly predict hepatocarcinogenesis?
Gin‐Ho Lo – 12 February 2014
Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C
Julien Vergniol, Jérôme Boursier, Clélia Coutzac, Sandrine Bertrais, Juliette Foucher, Camille Angel, Faiza Chermak, Isabelle Fouchard Hubert, Wassil Merrouche, Frédéric Oberti, Victor Lédinghen, Paul Calès – 12 February 2014 – No data are available about the prediction of long‐term survival using repeated noninvasive tests of liver fibrosis in chronic hepatitis C (CHC). We aimed to assess the prognostic value of 3‐year liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI), and fibrosis 4 (FIB‐4) evolution in CHC.